Sensorium Therapeutics describers new SERT inhibitors
Oct. 31, 2024
Sensorium Therapeutics Inc. has synthesized mesembrine derivatives acting as serotonin transporter (SERT) inhibitors reported to be useful for the treatment of anxiety, depression and stress disorders.